Generic Name and Formulations:
Dexamethasone 0.1%; oph susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for MAXIDEX:
Adults and Children:
Instill 1–2 drops in the affected eye(s). Severe: may administer hourly, then taper as condition improves. Mild: may administer up to 4–6 times daily.
Acute, untreated bacterial, fungal, mycobacterial, epithelial herpes simplex, or viral (except herpes zoster) infections of the eye.
Corneal or scleral thinning. Glaucoma. Monitor for secondary infections and intraocular pressure if used for ≥10 days. Avoid abrupt cessation. Pregnancy. Nursing mothers.
Local irritation, ocular discomfort, increased intraocular pressure, cataracts, corneal perforations, optic nerve damage; may mask or exacerbate infections.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline